title: Evaluating the risks and benefits of phase II and III cancer clinical trials: a look at Institutional Review Board members in the Netherlands.
authors.affiliation: Department of Philosophy, Vrije Universiteit, Amsterdam, The Netherlands.
authors.forename: H E M
authors.initials: HE
authors.lastname: Van Luijn
authors.forename: A W
authors.initials: AW
authors.lastname: Musschenga
authors.forename: R B
authors.initials: RB
authors.lastname: Keus
authors.forename: N K
authors.initials: NK
authors.lastname: Aaronson
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D028744:Ethics Committees, Research; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009426:Netherlands; D010358:Patient Participation / Q000523:psychology; D018570:Risk Assessment / Q000379:methods*